Scientists at the University of New Mexico have advanced a tau-targeting Alzheimer’s vaccine into human trials. It triggered strong immune reactions and cleared pathological tau protein in both mice and rhesus macaques — slowing neurodegeneration and improving cognition. A Phase 1 clinical trial is slated for early 2026 to assess safety and immune response in humans. This could mark the first step toward a true disease-modifying treatment. Could this be the breakthrough Alzheimer’s patients have been waiting for? For more content like this, please visit: https://t.co/wYpbt8knJz #alzheimersresearch# #tauvaccine# #medicalinnovation# #neuroscience#